- Trials with a EudraCT protocol (219)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
219 result(s) found for: Mini-mental state examination.
Displaying page 1 of 11.
EudraCT Number: 2018-000148-24 | Sponsor Protocol Number: 1 | Start Date*: 2018-06-14 |
Sponsor Name:Norwegian University of Science and Technology | ||
Full Title: Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: the ExPlas Study | ||
Medical condition: Early Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000955-40 | Sponsor Protocol Number: CI-1008-152 | Start Date*: 2004-09-23 |
Sponsor Name:Pfizer Global Research & Development | ||
Full Title: A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder | ||
Medical condition: Generalized Anxiety Disorder | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002303-18 | Sponsor Protocol Number: ISS112 | Start Date*: 2012-11-02 |
Sponsor Name:VU University Medical Center (VUmc) | ||
Full Title: The Dutch Flutemetamol in Young Dementia Study | ||
Medical condition: Young (age of diagnosis ≤ 70 years) patients with (suspicion of) dementia with at least some doubt about etiological diagnosis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004848-29 | Sponsor Protocol Number: NN6535-4730 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004864-25 | Sponsor Protocol Number: NN6535-4725 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004129-89 | Sponsor Protocol Number: Motor-Neuromod_01, Part I-III | Start Date*: 2005-09-19 |
Sponsor Name:Universitätsklinikum Münster | ||
Full Title: Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation | ||
Medical condition: Healthy volunteers Patients in the chronic stage (> 1 year) after stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-002316-12 | Sponsor Protocol Number: SR052012 | Start Date*: 2012-08-14 |
Sponsor Name:University Hospitals of the KU Leuven | ||
Full Title: The safety and feasibility of administering xenon to patients undergoing off-pump coronary artery bypass graft surgery: a pilot study XOPCAB – Xenon in Off-Pump Coronary Artery Bypass Grafting | ||
Medical condition: Xenon anesthesia in cardiac surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000485-11 | Sponsor Protocol Number: SR022013 | Start Date*: 2013-04-24 |
Sponsor Name:University Hospitals of the KU Leuven | ||
Full Title: Xenon as an adjuvant to propofol anaesthesia in patients undergoing off-pump coronary artery bypass graft surgery: a randomized controlled trial | ||
Medical condition: Xenon anesthesia in cardiac surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005313-35 | Sponsor Protocol Number: 14548 | Start Date*: 2008-01-29 |
Sponsor Name:GGZ Drenthe | ||
Full Title: Clinical effects of low dose pipamperon (Dipiperon) versus placebo on cognitive functions of elderly patients suffering from cognitive dysfunction, admitted at a general hospital. | ||
Medical condition: Elderly patients admitted at hospital often show cognitive dysfunction on behalf of their illness, disturbance of their familiar daily routine, change of surroundings and medical interventions. Bas... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024424-26 | Sponsor Protocol Number: AB10013 | Start Date*: 2015-05-05 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associ... | |||||||||||||
Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prohibited by CA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005548-25 | Sponsor Protocol Number: RNOP-12 | Start Date*: 2008-07-28 |
Sponsor Name:Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg | ||
Full Title: Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in... | ||
Medical condition: Patients with high-grade gliomas (world health organisation [WHO] grade III or IV) in the first relapse after first-line therapy including chemotherapy with or without nitrososurea, with a life exp... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-002653-30 | Sponsor Protocol Number: EVP-6124-025 | Start Date*: 2014-03-18 | ||||||||||||||||
Sponsor Name:EnVivo Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previou... | ||||||||||||||||||
Medical condition: Mild to moderate Alzheimer's disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000792-11 | Sponsor Protocol Number: | Start Date*: 2014-07-09 |
Sponsor Name:University of Warwick | ||
Full Title: Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest | ||
Medical condition: Out of hospital cardiac arrest | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019672-76 | Sponsor Protocol Number: RBHP2010CAILLAUD | Start Date*: 2010-10-12 |
Sponsor Name:CHU de Clermont-Ferrand | ||
Full Title: Impact de la correction du déficit en vitamine D chez les patients porteurs de syndrome d’apnées- hypopnées obstructives du sommeil. | ||
Medical condition: Syndrome d’apnées du sommeil (SAHOS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005001-29 | Sponsor Protocol Number: ZEN-006-Z030 | Start Date*: 2006-05-09 |
Sponsor Name:Zentaris GmbH | ||
Full Title: Efficacy and safety of ozarelix acetate, a new GnRH antagonist in male patients with mild to moderate Alzheimer’s Disease (Regimen: 130 mg q4w, x3) | ||
Medical condition: Male patients with mild to moderate Alzheimer´ Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000214-30 | Sponsor Protocol Number: P000805 | Start Date*: 2017-08-18 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Freiburg | ||||||||||||||||||
Full Title: Empagliflozin and its effect on heart failure in type 2 diabetes | ||||||||||||||||||
Medical condition: Heart failure and type 2 diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000356-18 | Sponsor Protocol Number: 25051974 | Start Date*: 2023-12-21 |
Sponsor Name:Stichting Apotheek der Haarlemse Ziekenhuizen | ||
Full Title: Effect of repeated intranasal cobalamin administration on cobalamin deficiency in elderly | ||
Medical condition: Cobalamin (vitamin B12) deficiency | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016955-23 | Sponsor Protocol Number: ASCOTALCO | Start Date*: 2010-06-25 | |||||||||||
Sponsor Name:AZIENDA USL 2 DI LUCCA | |||||||||||||
Full Title: Assessment of association efficacy of colinergic precursor and cholinesterasic inhibitor somministered transdermal in patient with Alzheimer`s disease and severe behavioural disturbances | |||||||||||||
Medical condition: patient with Alzheimer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001184-39 | Sponsor Protocol Number: FBPASL5-01 | Start Date*: 2015-09-17 | |||||||||||
Sponsor Name:ASL 5 SPEZZINO | |||||||||||||
Full Title: Assessing Florbetaben PET Patterns in MCI Patients for an Improved Prediction of Conversion to AD | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002855-25 | Sponsor Protocol Number: EIP-VX00-745-302 | Start Date*: 2015-03-11 | |||||||||||
Sponsor Name:EIP Pharma, LLC | |||||||||||||
Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ... | |||||||||||||
Medical condition: Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
